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Original Article

Pharmacomechanical Catheter-Directed
Thrombolysis for Deep-Vein Thrombosis
S. Vedantham, S.Z. Goldhaber, J.A. Julian, S.R. Kahn, M.R. Jaff, D.J. Cohen,
E. Magnuson, M.K. Razavi, A.J. Comerota, H.L. Gornik, T.P. Murphy, L. Lewis,
J.R. Duncan, P. Nieters, M.C. Derfler, M. Filion, C.-S. Gu, S. Kee, J. Schneider,
N. Saad, M. Blinder, S. Moll, D. Sacks, J. Lin, J. Rundback, M. Garcia, R. Razdan,
E. VanderWoude, V. Marques, and C. Kearon, for the ATTRACT Trial Investigators*

A BS T R AC T
BACKGROUND
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MO 63110, or at vedanthams@wustl.edu.
* A complete list of investigators in the
ATTRACT trial is provided in the Supplementary Appendix, available at NEJM.org.
This article was updated on December 7,
2017, at NEJM.org.
N Engl J Med 2017;377:2240-52.
DOI: 10.1056/NEJMoa1615066
Copyright © 2017 Massachusetts Medical Society.

The post-thrombotic syndrome frequently develops in patients with proximal deep-vein
thrombosis despite treatment with anticoagulant therapy. Pharmacomechanical catheterdirected thrombolysis (hereafter “pharmacomechanical thrombolysis”) rapidly removes
thrombus and is hypothesized to reduce the risk of the post-thrombotic syndrome.
METHODS

We randomly assigned 692 patients with acute proximal deep-vein thrombosis to receive either anticoagulation alone (control group) or anticoagulation plus pharmaco
mechanical thrombolysis (catheter-mediated or device-mediated intrathrombus delivery of recombinant tissue plasminogen activator and thrombus aspiration or
maceration, with or without stenting). The primary outcome was development of the
post-thrombotic syndrome between 6 and 24 months of follow-up.
RESULTS

Between 6 and 24 months, there was no significant between-group difference in the
percentage of patients with the post-thrombotic syndrome (47% in the pharmacomechanical-thrombolysis group and 48% in the control group; risk ratio, 0.96; 95%
confidence interval [CI], 0.82 to 1.11; P = 0.56). Pharmacomechanical thrombolysis led
to more major bleeding events within 10 days (1.7% vs. 0.3% of patients, P = 0.049),
but no significant difference in recurrent venous thromboembolism was seen over the
24-month follow-up period (12% in the pharmacomechanical-thrombolysis group and
8% in the control group, P = 0.09). Moderate-to-severe post-thrombotic syndrome occurred in 18% of patients in the pharmacomechanical-thrombolysis group versus 24%
of those in the control group (risk ratio, 0.73; 95% CI, 0.54 to 0.98; P = 0.04). Severity
scores for the post-thrombotic syndrome were lower in the pharmacomechanicalthrombolysis group than in the control group at 6, 12, 18, and 24 months of follow-up
(P<0.01 for the comparison of the Villalta scores at each time point), but the improvement in quality of life from baseline to 24 months did not differ significantly between
the treatment groups.
CONCLUSIONS

Among patients with acute proximal deep-vein thrombosis, the addition of pharmacomechanical catheter-directed thrombolysis to anticoagulation did not result in
a lower risk of the post-thrombotic syndrome but did result in a higher risk of
major bleeding. (Funded by the National Heart, Lung, and Blood Institute and others;
ATTRACT ClinicalTrials.gov number, NCT00790335.)
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D

espite the use of anticoagulant
therapy, the post-thrombotic syndrome
develops within 2 years in approximately
half of patients with proximal deep-vein thrombosis.1-4 The post-thrombotic syndrome commonly causes chronic limb pain and swelling and
can progress to cause major disability, leg ulcers,
and impaired quality of life.5,6 Small randomized
trials have suggested that active removal of acute
thrombus may preserve venous function and prevent the post-thrombotic syndrome (the “openvein hypothesis”).3,7,8
Pharmacomechanical catheter-directed thrombolysis (hereafter “pharmacomechanical thrombolysis”) is the delivery of a fibrinolytic drug
into the thrombus with concomitant thrombus
aspiration or maceration.9 The objective of pharmacomechanical thrombolysis is to diminish the
thrombus burden by means of low-dose fibrinolysis and mechanical therapy, thereby reducing
the risk of the post-thrombotic syndrome while
minimizing the risk of bleeding.10-13 We performed the Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed
Thrombolysis (ATTRACT) trial to determine
whether pharmacomechanical thrombolysis prevents the post-thrombotic syndrome in patients
with proximal deep-vein thrombosis.

steering committee vouches for the accuracy and
completeness of the data and the analyses and
for the fidelity of the trial to the protocol, which
is available at NEJM.org.
Patient Population

Patients with symptomatic proximal deep-vein
thrombosis involving the femoral, common femoral, or iliac vein (with or without other involved
ipsilateral veins) were enrolled at 56 clinical centers in the United States. Patients were excluded
if they were younger than 16 or older than 75
years of age, were pregnant, had had symptoms
for more than 14 days, were at high bleeding risk,
had active cancer, had established post-thrombotic syndrome, or had had ipsilateral deep-vein
thrombosis in the previous 2 years. The full list
of eligibility criteria, investigators, and sites is
provided in the Supplementary Appendix. All
the patients provided written informed consent.
Randomization

Patients were randomly assigned in a 1:1 ratio to
the pharmacomechanical-thrombolysis group or
the control group (no procedural intervention)
with the use of a Web-based central randomization system that ensured concealment of the treatment assignments. Randomization was stratified
according to clinical center and thrombus extent
(i.e., whether thrombosis involved the common
Me thods
femoral or iliac vein [iliofemoral deep-vein
Trial Organization
thrombosis] or not [femoropopliteal deep-vein
We conducted a phase 3, multicenter, random- thrombosis]). The randomization sequence, with
ized, open-label, assessor-blinded, controlled varying block sizes, was computer-generated by
clinical trial sponsored by the National Heart, an independent statistician.
Lung, and Blood Institute of the National Institutes of Health. Boston Scientific and Covidien Treatment and Outcome Assessments
(now Medtronic) provided supplemental funding. Patients in each treatment group received initial
The trial drug and additional funding were pro- and long-term anticoagulant therapy consistent
vided by Genentech. Compression stockings were with published guidelines, including the option
donated by BSN Medical. These companies played of rivaroxaban when it became available, and were
no role in the design or conduct of the trial or provided sized-to-fit, knee-high, elastic compresin the analysis or reporting of the data.
sion stockings providing 30 to 40 mm Hg of
The trial was approved by the institutional pressure (BSN Medical) at the 10-day follow-up
review boards at all participating centers. The visit and every 6 months.15,16 Pharmacomechanical
steering committee and site investigators were catheter-directed thrombolysis was performed in
responsible for the design14 and conduct of the a manner consistent with published guidelines by
trial, respectively. The contract research organi- board-certified physicians whose credentials were
zation Inclinix provided guidance to support approved by the trial leadership.14,17,18 A detailed
participant-recruitment efforts, and data analy- description of these methods is provided in the
ses were conducted by the trial statistical staff Supplementary Appendix.
(see the Supplementary Appendix, available with
Recombinant tissue plasminogen activator
the full text of this article at NEJM.org). The (rt-PA) (alteplase [Activase, Genentech] at a dose
n engl j med 377;23
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of <35 mg) was delivered into the thrombus by
one of three methods. If the popliteal vein was
occluded or the inferior vena cava was involved,
physicians were required to use “infusion-first”
therapy, which started with rt-PA infusion
through a multi-sidehole catheter of the physician’s choice for no longer than 30 hours. For
the remaining patients, physicians were required
to first attempt single-session thrombus removal
with rapid delivery of rt-PA through the AngioJet
Rheolytic Thrombectomy System (Boston Scientific) or the Trellis Peripheral Infusion System
(Covidien) and then to infuse rt-PA for no longer
than 24 hours if residual thrombus was present.
After the initial delivery of rt-PA, physicians
could use balloon maceration, catheter aspiration,
thrombectomy with the use of the AngioJet or
Trellis system, percutaneous transluminal balloon
venoplasty, stent placement (iliac or common
femoral vein), or a combination of procedures to
clear residual thrombus and treat obstructive
lesions.17,18 Stenting was encouraged for lesions
that were causing 50% or greater narrowing of the
diameter of the vein, robust collateral filling, or a
mean pressure gradient of more than 2 mm Hg.
Treatment was discontinued when there was at
least 90% thrombus removal with restoration of
flow or when there was a serious complication.
The international normalized ratio was required to be 1.6 or lower at the start of pharmaco
mechanical thrombolysis. During the procedure,
patients received twice-daily subcutaneous injections of low-molecular-weight heparin in therapeutic doses or unfractionated heparin infusions
(with the dose reduced to 6 to 12 units per kilogram of body weight per hour [maximum, 1000
units per hour] during rt-PA infusions). Additional
unfractionated heparin boluses (up to 50 units
per kilogram) were given during the procedure
at the physician’s discretion.
Trial outcomes were assessed at 10 and 30 days
and 6, 12, 18, and 24 months after randomization. The clinical personnel who performed assessments of efficacy outcomes and the adjudicators of safety and efficacy outcomes were unaware
of the treatment assignments.
Primary Efficacy Outcome

Development of the post-thrombotic syndrome,
the primary efficacy outcome, was defined as a
Villalta score of 5 or higher or an ulcer in the leg
with the index deep-vein thrombosis, at any time
2242
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between the 6-month follow-up visit and the
24-month follow-up visit.19,20 The Villalta scale
ranges from 0 to 33, with higher scores indicating more severe post-thrombotic syndrome (details are provided in the Supplementary Appendix). Patients were also counted as having the
post-thrombotic syndrome if they underwent an
unplanned endovascular procedure to treat severe venous symptoms beyond 6 months after
randomization, unless a Villalta score within the
previous 4 weeks was lower than 5.
Secondary Efficacy and Safety Outcomes

The occurrence of the post-thrombotic syndrome
at 6, 12, 18, and 24 months was counted if the
Villalta score at that visit was 5 or higher. The
severity of the post-thrombotic syndrome was
evaluated at 6, 12, 18 and 24 months with the
use of the Villalta scale and the Venous Clinical
Severity Score21 (scores range from 0 to 27, with
higher scores indicating more severe postthrombotic syndrome). The proportion of patients with moderate-to-severe post-thrombotic
syndrome (Villalta score, ≥10) was also assessed.
A major non–post-thrombotic syndrome treatment failure was assessed when any of three
events occurred in the index leg: an unplanned
endovascular procedure to treat severe venous
symptoms within 6 months, venous gangrene
within 6 months, or an amputation within 24
months. The combined outcome of the postthrombotic syndrome or major non–post-thrombotic syndrome treatment failure was also assessed.
Patient-reported health-related quality of life
at baseline and 24 months was assessed with the
use of the generic Medical Outcomes Study 36Item Short Form Health Survey (SF-36)22 and the
venous disease–specific Venous Insufficiency
Epidemiological and Economic Study Quality of
Life (VEINES-QOL) measure.23 Leg pain and leg
swelling at baseline, 10 days, and 30 days were
assessed with the use of a 7-point Likert pain
scale (with higher scores indicating more severe
pain)24 and by measuring calf circumference,
respectively.
In the pharmacomechanical-thrombolysis
group, thrombus removal was quantified by independent central readers who scored venograms
obtained before and after the procedure, using
the proximal-vein components of the Marder
score.25 The modified Marder score ranges from
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0 to 24, with 0 representing no thrombus and 24
representing complete thrombosis.
Safety outcomes included bleeding, recurrent
venous thromboembolism, and death, which were
reported throughout follow-up and summarized
through 10 days and 24 months.26 A detailed
description of all trial outcomes is provided in
the Supplementary Appendix.
Statistical Analysis

We estimated that the post-thrombotic syndrome
would develop in 30% of the patients in the
control group between 6 and 24 months1,27-29 and
hypothesized that pharmacomechanical thrombolysis would reduce this percentage to 20% or
lower.30-33 Assuming a 10% loss to follow-up, we
calculated that 692 patients would be required in
order for the trial to have 80% power to detect
the hypothesized treatment effect at a two-sided
α of 0.05.
Two types of analyses were performed: a modified intention-to-treat analysis that included all
patients who underwent randomization except
those who did not have deep-vein thrombosis at
enrollment, and a per-protocol analysis that excluded patients who, within 7 days after randomization, were randomly assigned to receive pharmacomechanical thrombolysis but did not receive
it or who were randomly assigned to the control
group but had skin puncture for pharmacomechanical thrombolysis or any thrombolytic therapy.
The primary analysis was a modified intentionto-treat analysis that compared the cumulative
proportion of patients who had development of
the post-thrombotic syndrome within 24 months
between the treatment groups with the use of the
Cochran–Mantel–Haenszel test with adjustment
for the two stratification variables. A two-sided
P value of 0.05 or lower was considered to indicate statistical significance. The treatment effects
are summarized with the use of stratum-adjusted
risk ratios and their corresponding 95% confidence intervals. To account for the missing assessments during follow-up, a sensitivity analysis
with multiple imputation, under the assumption
that data were missing at random, was conducted
on the Cochran–Mantel–Haenszel risk-ratio estimates with the use of prespecified auxiliary
variables (age, sex, body-mass index, extent of
deep-vein thrombosis, the maximum Villalta score
observed at assessments from 6 to 24 months,
and available Villalta scores at baseline, 10 days,
n engl j med 377;23

or 30 days). Details are provided in the Supplementary Appendix.
Prespecified secondary analyses included a perprotocol analysis of the primary outcome and
modified intention-to-treat and per-protocol analyses of each of the secondary efficacy outcomes.
Stratum-adjusted Cochran–Mantel–Haenszel tests
were used for the analysis of each of the categorical secondary outcomes and safety outcomes.
The mean Villalta and Venous Clinical Severity
Score assessments at each visit were estimated
with the use of piecewise linear-regression
growth-curve models with adjustment for strata
and prespecified baseline covariates (age, sex,
body-mass index, and Villalta score). Changes
from baseline to 24 months in quality-of-life
scores and from baseline to 10 and 30 days in
leg-pain scores and calf circumferences were
compared between the two treatment groups by
means of linear regression with adjustment for
strata. To account for multiple testing, a twosided P value of 0.01 or lower was considered to
indicate statistical significance for the secondary
efficacy analyses. A two-sided P value of 0.05 or
lower was considered to indicate statistical significance for the safety analyses.

R e sult s
Characteristics of the Patients at Baseline

From December 2009 through December 2014, a
total of 692 patients underwent randomization
(337 to the pharmacomechanical-thrombolysis
group and 355 to the control group) (Fig. 1). One
patient who was assigned to the pharmaco
mechanical-thrombolysis group was excluded from
all analyses; on review of prerandomization
assessments by personnel who were unaware of
the treatment assignments, this patient was found
not to have a qualifying deep-vein thrombosis.
The baseline characteristics of the patients were
similar in the treatment groups (Table 1, and
Table S2 in the Supplementary Appendix).
Protocol and Treatment Adherence

Within 7 days after randomization, 5 patients who
had been assigned to the control group underwent pharmacomechanical thrombolysis, and 11
patients who had been assigned to the pharmaco
mechanical-thrombolysis group did not undergo
the procedure. These patients were excluded from
the per-protocol analysis. The use of anticoagula-
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26,715 Were excluded
1,100 Declined to participate

Post-Thrombotic Syndrome

692 Underwent randomization

In the primary analysis, the post-thrombotic syndrome developed over the 24-month period in
157 of 336 patients (47%) assigned to the pharmacomechanical-thrombolysis group and in 171
of 355 patients (48%) assigned to the control
group (risk ratio, 0.96; 95% CI, 0.82 to 1.11;
P = 0.56) (Table 3). The findings were similar in
a per-protocol analysis (151 of 325 patients who
underwent pharmacomechanical thrombolysis
and 169 of 350 who did not undergo pharmaco
mechanical thrombolysis; risk ratio, 0.94; 95%
CI, 0.81 to 1.10) and in a sensitivity analysis with
multiple imputation (risk ratio, 0.89; 95% CI,
0.78 to 1.02) (Tables S3 and S4 in the Supplementary Appendix). The results were similar in
prespecified subgroups (Fig. S1 in the Supplementary Appendix), except for a suggestion that
patients 65 years of age or older were less likely
to benefit from pharmacomechanical thrombo
lysis than younger patients (P = 0.04 for the interaction).

1 Was excluded after
randomization

355 Were assigned to control group

336 Were assigned to
pharmacomechanical-thrombolysis
group

5 Received pharmacomechanical
thrombolysis in first 7 days
12 Underwent LEP during 24 mo

11 Did not receive pharmacomechanical thrombolysis in first 7 days
20 Underwent LEP during 24 mo

257 Completed 24 mo of follow-up
79 Were followed <24 mo
7 Died
10 Withdrew consent
62 Were lost to follow-up

194 Completed 4 PTS assessments
109 Completed 1–3 PTS assessments
52 Missed all 4 PTS assessments

215 Completed 4 PTS assessments
93 Completed 1–3 PTS assessments
28 Missed all 4 PTS assessments

355 Were included in the modified
intention-to-treat analysis
350 Were included in the per-protocol
analysis

336 Were included in the modified
intention-to-treat analysis
325 Were included in the per-protocol
analysis

Secondary Efficacy Outcomes

Figure 1. Enrollment, Randomization, and Follow-up.
The reasons for the exclusion of patients before randomization are shown
in Table S1 in the Supplementary Appendix. Randomization was stratified
according to clinical center and extent of deep-vein thrombosis. Two patients
(one in each treatment group) missed all four assessments for the postthrombotic syndrome (PTS) because they died before 6 months. LEP denotes
late endovascular procedure.

tion and compression stockings and the elements
of pharmacomechanical thrombolysis are summarized in Table 2. The mean duration of anticoagulation before the first permanent cessation
was similar in the two treatment groups (median
days to stopping, 211 days in the pharmaco
mechanical-thrombolysis group and 231 days in
the control group; P = 0.16) (Table 2). Pharmaco
2244
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mechanical thrombolysis was performed at a median of 1 day after randomization. The mean
degree of thrombus removal was 76% (mean preprocedure Marder score, 11.4; mean postprocedure Marder score, 2.7; change, −8.7; 95% confidence interval [CI], −8.1 to −9.4; P<0.001).

28,507 Patients met inclusion criteria

243 Completed 24 mo of follow-up
112 Were followed <24 mo
8 Died
18 Withdrew consent
86 Were lost to follow-up

of

n engl j med 377;23

There was no significant between-group difference in the percentage of patients who had major non–post-thrombotic syndrome treatment
failure or overall treatment failure (P≤0.01 was
considered to indicate statistical significance for
the secondary efficacy analyses) (Table 3). Moderate-to-severe post-thrombotic syndrome (Villalta
score, ≥10) occurred in 18% of the patients in
the pharmacomechanical thrombolysis group and
24% of those in the control group (risk ratio,
0.73; 95% CI, 0.54 to 0.98; P = 0.04). The severity
of the post-thrombotic syndrome, as assessed by
the mean Villalta score and mean Venous Clinical Severity Score, was significantly lower in the
pharmacomechanical-thrombolysis group than
in the control group at all visits between 6 and
24 months (P≤0.01 for the between-group comparison at each time point, with the exception of
the comparison of the Venous Clinical Severity
Score at 24 months, for which P=0.03) (Table 4).
Over the 24-month period, there was no signifi-
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Table 1. Characteristics of the Patients at Baseline.*
PharmacomechanicalThrombolysis Group
(N = 336)

Control Group
(N = 355)

Total
(N = 691)

52 (41–62)

53 (43–62)

53 (42–62)

205 (61)

221 (62)

426 (62)

White

265 (79)

276 (78)

541 (78)

Black

61 (18)

62 (17)

123 (18)

Characteristic
Median age (IQR) — yr
Male sex — no. (%)
Race — no. (%)†

10 (3)

17 (5)

27 (4)

Median weight (IQR) — kg

Other

95 (81–111)

92 (79–110)

93 (80–110)

Median body-mass index (IQR)‡

31 (27–36)

30 (26–35)

31 (27–35)

0–4

57 (17)

69 (19)

126 (18)

5–9

115 (34)

124 (35)

239 (35)

98 (29)

94 (26)

192 (28)

Villalta score — no. (%)§

10–14

66 (20)

66 (19)

132 (19)

Index deep-vein thrombosis in left leg — no. (%)

≥15

207 (62)

218 (61)

425 (62)

Deep-vein thrombosis extends into common femoral vein, iliac vein,
or both — no. (%)

195 (58)

196 (55)

391 (57)

Previous deep-vein thrombosis or pulmonary embolism — no. (%)

83 (25)

87 (25)

170 (25)

5 (1)

14 (4)

19 (3)

Major surgery

27 (8)

34 (10)

61 (9)

Hospitalization

26 (8)

38 (11)

64 (9)

8 (2)

9 (3)

17 (2)

Previous ipsilateral deep-vein thrombosis — no. (%)
Deep-vein thrombosis risk factors — no. (%)¶

Plaster cast immobilization

3 (1)

5 (1)

8 (1)

Outpatient — no. (%)

Childbirth

268 (80)

300 (85)

568 (82)

Median interval from start of symptoms of deep-vein thrombosis
to randomization (IQR) — days

6 (4–10)

6 (4–9)

6 (4–10)

Aspirin use within 7 days before randomization — no. (%)

68 (20)

74 (21)

142 (21)

86 (70–102)

86 (71–102)

86 (71–102)

314 (93)

331 (93)

645 (93)

180 (57)

205 (62)

385 (60)

Unfractionated heparin

99 (32)

99 (30)

198 (31)

Rivaroxaban

16 (5)

11 (4)

27 (4)

Other

18 (5)

16 (5)

34 (5)

154 (49)

179 (57)

333 (52)

Median estimated glomerular filtration rate (IQR) — ml/min
Prerandomization anticoagulant therapy — no. (%)¶‖
Low-molecular-weight heparin

Warfarin

*	IQR denotes interquartile range.
†	Race was reported by the patient.
‡	Body-mass index is the weight in kilograms divided by the square of the height in meters.
§	The Villalta scale is an assessment of five patient-reported symptoms (cramps, itching, pins and needles, leg heaviness, and pain) and six
signs reported by clinicians who were unaware of the treatment assignments (pretibial edema, skin induration, hyperpigmentation, venous
ectasia, redness, and pain during calf compression), scored on a 4-point scale (a score of 0 denotes none or minimal, 1 mild, 2 moderate,
and 3 severe) and summed into a total score for each leg; a leg with an ulcer was assigned a minimum score of 15 points. Total scores range
from 0 to 33, with higher scores indicating more severe post-thrombotic syndrome; a score of 0 to 4 denotes none or minimal, 5 to 9 mild,
10 to 14 moderate, and 15 or higher severe. Two patients in the control group were not assessed.
¶	Patients could be included in more than one category.
‖	Anticoagulant therapy that was given after the diagnosis of deep-vein thrombosis and before randomization is shown.
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Table 2. Treatment after Randomization.*
PharmacomechanicalThrombolysis Group
(N = 336)

Control Group
(N = 355)

Unfractionated heparin

118/334 (35)

69/352 (20)

Low-molecular-weight heparin

181/334 (54)

227/352 (64)

49/334 (15)

71/352 (20)

314/321 (98)

316/322 (98)

47/321 (15)

43/322 (13)

252/321 (79)

252/322 (78)

227/290 (78)

247/286 (86)

60/290 (21)

38/286 (13)

192/290 (66)

197/286 (69)

120/251 (48)

117/236 (50)

71/251 (28)

62/236 (26)

138/251 (55)

130/236 (55)

Treatment
Initial anticoagulant therapy — no./total no. (%)†‡

Other
Therapy at 30 days — no./total no. (%)‡
Any anticoagulant therapy
Antiplatelet therapy
Compression stockings used ≥3 days/wk
Therapy at 6 mo — no./total no. (%)‡
Any anticoagulant therapy
Antiplatelet therapy
Compression stockings used ≥3 days/wk
Therapy at 24 mo — no./total no. (%)‡
Any anticoagulant therapy
Antiplatelet therapy
Compression stockings used ≥3 days/wk
Duration of anticoagulant therapy
Never started — no. (%)
Not stopped during trial period — no. (%)
Stopped during trial period — no. (%)
Median days to stopping (IQR)

2 (1)

3 (1)

185 (55)

203 (57)

149 (44)

149 (42)

211 (179–360)

231 (189–371)

194 (58)

—

Details of pharmacomechanical thrombolysis
Initial rt-PA delivery method
Infusion-first — no. (%)
Median rt-PA total dose (IQR) — mg
rt-PA duration — hr§
% with duration <4 hr
AngioJet — no. (%)
Median rt-PA total dose (IQR) — mg
rt-PA duration — hr§
% with duration <4 hr
Trellis — no. (%)
Median rt-PA total dose (IQR) — mg
rt-PA duration — hr§
% with duration <4 hr
Other — no. (%)¶

21 (18–26)

—

22±6.5

—

0

—

75 (22)

—

21 (12–28)

—

20±5.3

—

45

—

50 (15)

—

20 (12–25)

—

19±5.7

—

62

—

17 (5)

—

39 (12)

—

297 (88)

—

Additional endovascular methods used — no. (%)
None
1 or more

2246
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Table 2. (Continued.)
PharmacomechanicalThrombolysis Group
(N = 336)

Control Group
(N = 355)

Balloon venoplasty

184/297 (62)

—

Balloon maceration

183/297 (62)

—

Rheolytic thrombectomy with AngioJet

180/297 (61)

—

Stent placement

82/297 (28)

—

Large-bore catheter aspiration

63/297 (21)

—

Isolated thrombolysis with Trellis

14/297 (5)

—

Wallstent (Boston Scientific)

34/82 (41)

—

SMART (Cordis)

12/82 (15)

—

Protégé (Covidien [now Medtronic])

Treatment
Type of additional method — no./total no. (%)‡

Type of stent placed — no./total no. (%)‡

10/82 (12)

—

Zilver (Cook Medical)

6/82 (7)

—

Luminexx (C.R. Bard)

5/82 (6)

—

Lifestar (C.R. Bard)

2/82 (2)

—

EPIC (Boston Scientific)

2/82 (2)

—

Viabahn (Gore)

1/82 (1)

—

Multiple types

7/82 (9)

—

Not specified

3/82 (4)

—

*	Plus–minus values are means ±SD. The abbreviation rt-PA denotes recombinant tissue plasminogen activator.
†	Anticoagulant therapy given after randomization is shown.
‡	Patients could be included in more than one category.
§	Distributions are bimodal, with spikes below 4 hours (means and standard deviations are for data after 4 hours).
¶	Other includes 10 procedures in which there was no acute thrombus found on venogram and 7 that were not attempted.

cant between-group difference in the change in
venous disease–specific quality of life (P = 0.08)
or general quality of life (P = 0.37). The mean
decreases in leg pain from baseline in the
pharmaco
mechanical-thrombolysis group and
the control group were 1.62 and 1.29 Likert
points at 10 days, respectively (P = 0.02), and 2.17
and 1.83 Likert points at 30 days, respectively
(P = 0.03). For leg circumference, a decrease of
0.26 cm and an increase of 0.27 cm from baseline at 10 days occurred in the pharmacomechan
ical-thrombolysis group and the control group,
respectively (P = 0.02), and decreases from baseline of 0.74 cm and 0.28 cm had occurred at 30
days, respectively (P = 0.05). The results of the
per-protocol analyses were similar to those of
the modified intention-to-treat analyses (Tables
S5 and S6 in the Supplementary Appendix).

n engl j med 377;23

Safety Outcomes

Major bleeding within 10 days occurred in 6 patients (1.7%) assigned to the pharmacomechanicalthrombolysis group, as compared with 1 patient
(0.3%) assigned to the control group (P = 0.049)
(Table 3). Details of the bleeding events are
shown in Table S7 in the Supplementary Appendix. Recurrent venous thromboembolism within
24 months occurred in 42 patients (12%) assigned to the pharmacomechanical-thrombolysis group (including 1 fatal pulmonary embolism at 6 months) and in 30 patients (8%)
assigned to the control group (P = 0.09). Of the
15 deaths that occurred (7 in the pharmaco
mechanical thrombolysis group and 8 in the
control group), none occurred within 10 days
after randomization (Table 3, and Table S8 in
the Supplementary Appendix).
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Table 3. Binary Trial Outcomes.
PharmacomechanicalThrombolysis Group
(N = 336)

Outcome

Control Group
(N = 355)

Risk Ratio (95% CI)

P Value

number of patients (percent)
Post-thrombotic syndrome between 6 and 24 mo*
Ulcer at any follow-up assessment
Villalta score ≥5 without ulcer
Late endovascular procedure only

12 (4)

17 (5)

144 (43)

154 (43)

1 (<1)

Total

0

157 (47)

171 (48)

0.96 (0.82–1.11)†

0.56

At 6 mo

78/291 (27)

113/285 (40)

0.68 (0.53–0.86)

At 12 mo

92/272 (34)

88/258 (34)

0.99 (0.78–1.26)

At 18 mo

85/245 (35)

76/222 (34)

1.01 (0.79–1.30)

At 24 mo

79/258 (31)

86/239 (36)

0.85 (0.66–1.09)

4 (1)

7 (2)

0.58 (0.17–1.98)§

0.38¶

158 (47)

176 (50)

0.94 (0.80–1.09)†

0.39¶

60 (18)

84 (24)

0.73 (0.54–0.98)†

0.04¶

6 (1.7)

1 (0.3)

6.18 (0.78–49.2)§

0.049

19 (5.7)

13 (3.7)

1.52 (0.76–3.01)§

0.23

Post-thrombotic syndrome according to follow-up visit‡

Major non–post-thrombotic syndrome treatment failure
Any treatment failure‖
Moderate-to-severe post-thrombotic syndrome**
Major bleeding††
First 10 days
Total over 24 mo
Any bleeding
First 10 days

15 (4)

6 (2)

2.64 (1.04–6.68)§

0.03

Total over 24 mo

46 (14)

38 (11)

1.26 (0.85–1.89)§

0.25

Recurrent venous thromboembolism
First 10 days
Total over 24 mo

6 (2)

4 (1)

1.53 (0.44–5.28)§

0.50

42 (12)

30 (8)

1.47 (0.94–2.29)§

0.09

0

0

7 (2)

8 (2)

0.89 (0.33–2.44)

0.83

Death
First 10 days
Total over 24 mo

*	Data are the cumulative percentage of patients in whom the post-thrombotic syndrome (ulcer, Villalta score ≥5, or late endovascular procedure) developed at any time from 6 through 24 months.
†	The estimate is from a Cochran–Mantel–Haenszel test with adjustment for the extent of deep-vein thrombosis and clinical center.
‡	Data are the percentage of patients at each visit with any post-thrombotic syndrome according to the Villalta scale among those who had
an assessment performed (denominator).
§	The estimate is from a Cochran–Mantel–Haenszel test with adjustment for the extent of deep-vein thrombosis.
¶	For the secondary efficacy analyses, a P value of 0.01 or lower was considered to indicate statistical significance.
‖	Data are for a composite of post-thrombotic syndrome or major non–post-thrombotic syndrome treatment failure.
**	Data are the cumulative percentage of patients with moderate or severe post-thrombotic syndrome (prespecified analysis), defined as a
Villalta score of 10 or higher.
††	More precise percentages are provided for major bleeding to show the magnitude of the between-group difference in risk.

Discussion
In this trial, pharmacomechanical thrombolysis
did not prevent the post-thrombotic syndrome in
patients with acute proximal deep-vein thrombosis; this finding persisted in per-protocol
2248
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analyses and was consistent across all prespecified subgroups. In the pharmacomechanicalthrombolysis group, there were more early major
bleeds than in the control group, but less major
bleeding (1.7% of patients, with no fatal or intracranial bleeds) occurred in association with the
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Table 4. Continuous Trial Outcomes.
PharmacomechanicalThrombolysis Group
(N = 336)

Outcome

Control Group
(N = 355)

Between-Group Difference

No. of
Patients

Mean ±SE

No. of
Patients

Mean ±SE

Estimate ±SE

P Value*

At 6 mo

291

3.11±0.24

285

4.33±0.24

−1.22±0.31

<0.001

At 12 mo

272

3.22±0.22

258

4.38±0.22

−1.17±0.28

<0.001

At 18 mo

245

3.32±0.24

222

4.44±0.24

−1.12±0.31

<0.001

At 24 mo

258

3.43±0.28

239

4.50±0.29

−1.06±0.38

0.005

At 6 mo

289

1.73±0.15

279

2.68±0.15

−0.95±0.21

<0.001

At 12 mo

265

1.80±0.16

253

2.37±0.16

−0.56±0.23

0.01

At 18 mo

240

1.74±0.17

215

2.80±0.18

−1.06±0.24

<0.001

At 24 mo

235

1.87±0.18

214

2.42±0.19

−0.55±0.26

0.03

PCS, baseline to 24 mo

245

11.18±0.91

222

10.06±0.97

1.13±1.26

0.37

MCS, baseline to 24 mo

245

2.70±0.84

222

2.70±0.89

0.00±1.16

0.99

Overall, baseline to 24 mo

249

27.67±1.71

226

23.47±1.83

4.20±2.39

0.08

Symptoms, baseline to 24 mo

248

20.58±1.70

226

17.31±1.81

3.27±2.37

0.17

Villalta score†

VCSS score†‡

Change in SF-36 general quality of life§¶

Change in VEINES disease-specific quality of
life¶‖

Change in leg-pain severity¶**
Baseline to day 10

317

−1.62±0.10

325

−1.29±0.10

−0.33±0.14

0.02

Baseline to day 30

314

−2.17±0.11

317

−1.83±0.11

−0.34±0.15

0.03

Baseline to day 10

305

−0.26±0.17

323

0.27±0.16

−0.53±0.23

0.02

Baseline to day 30

304

−0.74±0.17

315

−0.28±0.16

−0.46±0.23

0.05

Change in index-leg circumference — cm¶††

*	For the secondary efficacy analyses, a P value of 0.01 or lower was considered to indicate statistical significance.
†	Mean scores, standard errors, and between-group differences were estimated with the use of growth-curve models and piecewise linear regression with adjustment for the extent of deep-vein thrombosis and clinical center and for baseline covariates (age, sex, body-mass index,
and Villalta score).
‡	The Venous Clinical Severity Score (VCSS) ranges from 0 to 27, with higher scores indicating more severe post-thrombotic syndrome.
§	The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) includes a physical component score (PCS) and a mental component score (MCS). Each score ranges from 0 to 100, with higher scores indicating better quality of life. A difference of 3 to 4 points is
considered clinically meaningful.
¶	Mean changes in scores, standard errors, and between-group differences were estimated with the use of multiple linear regression with
adjustment for the extent of deep-vein thrombosis and clinical center.
‖	The Venous Insufficiency Epidemiological and Economic Study Quality of Life (VEINES-QOL) measure includes an overall score and a
symptom-specific score. Each score ranges from 0 to 100, with higher sores indicating better quality of life. A difference of 3 to 4 points
is considered clinically meaningful.
**	The patient-reported severity of pain in the index leg was measured on a Likert scale. Scores range from 0 to 7, with higher scores indicating more severe pain.
††	Leg circumference was measured at 10 cm below the tibial tuberosity of the index leg.

procedure than in past studies of thrombolysis
for deep-vein thrombosis.3,7,18,34-36
In the recent CAVENT (Catheter-Directed Venous Thrombolysis in Acute Iliofemoral Vein
Thrombosis) trial, catheter-directed thrombolyn engl j med 377;23

sis reduced the risk of the post-thrombotic syndrome over periods of 2 and 5 years.3,34 Our trial,
for uncertain reasons, did not confirm these
findings. Differences between the two trials include the larger size of our trial (692 vs. 209
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patients), its geographic and demographic scope
(56 U.S. centers vs. 4 Norwegian centers), and
our greater use of mechanical therapies versus
the longer rt-PA infusions used in the CAVENT
trial. Inadequate thrombus removal is unlikely
to explain the failure of pharmacomechanical
thrombolysis to prevent the post-thrombotic syndrome in our trial, since venography showed
effective thrombus removal. Standard care for
deep-vein thrombosis did not substantially differ
between the two treatment groups and would
not explain the observed lack of a beneficial effect of pharmacomechanical thrombolysis in preventing the post-thrombotic syndrome.
Our trial had several limitations. There was a
substantial number of missing assessments of
the post-thrombotic syndrome. As expected, there
were occasional missed visits among patients
who returned for follow-up, which were balanced
between the treatment groups. However, among
the 80 patients with no post-thrombotic syndrome assessments, two thirds were in the control group, which is likely to have resulted in an
underestimate of the treatment effect. Although
the sensitivity analysis conducted with the use of
methods to impute assessments of the postthrombotic syndrome in these patients yielded
findings similar to those in the primary analysis, the extent of incomplete follow-up is still a
limitation of the trial.
A large number of patients had to be screened
in order to enroll our target sample; this largely
reflects the exclusion of patients who would not
receive pharmacomechanical thrombolysis in clinical practice (e.g., patients with a high bleeding
risk), but it could reduce the generalizability of
the trial. The trial was medium-sized, but given
the risks of pharmacomechanical thrombolysis,
it was unlikely to miss a treatment effect of sufficient size to influence clinical practice. However, the trial had limited power to examine treatment effects within subgroups. Although many
elements of pharmacomechanical thrombolysis
were standardized, there was variation in how the
procedure was performed, in order to accommodate patient-specific differences and physician
preferences. We did not randomly assign patients
to specific treatment methods, which precluded
a direct comparison of outcomes among the
methods. Finally, most patients received warfarin; although direct oral anticoagulants are now
frequently used, this change should not have
2250
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affected the rates of the post-thrombotic syndrome, since both types of anticoagulation are
similarly effective at preventing recurrent deepvein thrombosis.15,37
Because the post-thrombotic syndrome varies
in its clinical manifestations, we evaluated its
presence and severity in complementary ways.
Assessments made with the use of the Villalta
scale and the Venous Clinical Severity Score were
consistent in suggesting that pharmacomechanical thrombolysis reduced the severity of the
post-thrombotic syndrome, which raises the possibility that the etiologic factors that predispose
patients to the development of the post-thrombotic syndrome may differ at least partly from
those that determine progression to advanced
post-thrombotic syndrome. Further study of the
open-vein hypothesis may help to define the
pathophysiological basis of the post-thrombotic
syndrome and identify opportunities to reduce
progression or alleviate disabling symptoms.
In conclusion, among patients with acute
proximal deep-vein thrombosis, the addition of
pharmacomechanical catheter-directed thrombolysis to anticoagulation did not result in a
lower risk of the post-thrombotic syndrome but
did result in a higher risk of major bleeding.
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